Laser diffraction particle sizing: Instrument probe volume relocation and elongation

The effective probe volume of laser diffraction particle sizing instruments depends on many instrument parameters. In particular the probe volume axial boundaries and its location along laser beam are essentially defined by the onset of a vignetting effect where light scattered at large angles from small particles misses the transform lens. This vignetting effect results in a probe volume that must be inconveniently close to the lens in order to detect smaller diameter particles (less than 100 micrometers). With the addition of an appropriately designed Keplerian telescope, the probe volume may be relocated and elongated. The theory of operation of this supplemental optical system is described. Design considerations for these supplemental optical systems are described, including recommendations for lens specifications, assembly and use. An image transfer system is described which has been designed for use on a Malvern 2600HSD instrument. Experimental validation of this image transfer system is described

New Chemicals May Help Trefoil Seed Harvest

Though birdsfoot trefoil sets between 200 and 300 pounds of seed per acre in Iowa, harvested yields are commonly only 40 to 60 pounds. Use of chemical desicants followed by direct combining offers a possible solution

Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial

BACKGROUND Normofractionated radiation regimes for definitive prostate cancer treatment usually extend over 7-8 weeks. Recently, moderate hypofractionation with doses per fraction between 2.2 and 4 Gy has been shown to be safe and feasible with oncologic non-inferiority compared to normofractionation. Radiobiologic considerations lead to the assumption that prostate cancer might benefit in particular from hypofractionation in terms of tumor control and toxicity. First data related to ultrahypofractionation demonstrate that the overall treatment time can be reduced to 5-7 fractions with single doses > 6 Gy safely, even with simultaneous focal boosting of macroscopic tumor(s). With MR-guided linear accelerators (MR-linacs) entering clinical routine, invasive fiducial implantations become unnecessary. The aim of the multicentric SMILE study is to evaluate the use of MRI-guided stereotactic radiotherapy for localized prostate cancer in 5 fractions regarding safety and feasibility. METHODS The study is designed as a prospective, one-armed, two-stage, multi-center phase-II-trial with 68 patients planned. Low- and intermediate-risk localized prostate cancer patients will be eligible for the study as well as early high-risk patients (cT3a and/or Gleason Score ≤ 8 and/or PSA ≤ 20 ng/ml) according to d'Amico. All patients will receive definitive MRI-guided stereotactic radiation therapy with a total dose of 37.5 Gy in 5 fractions (single dose 7.5 Gy) on alternating days. A focal simultaneous integrated boost to MRI-defined tumor(s) up to 40 Gy can optionally be applied. The primary composite endpoint includes the assessment of urogenital or gastrointestinal toxicity ≥ grade 2 or treatment-related discontinuation of therapy. The use of MRI-guided radiotherapy enables online plan adaptation and intrafractional gating to ensure optimal target volume coverage and protection of organs at risk. DISCUSSION With moderate hypofractionation being the standard in definitive radiation therapy for localized prostate cancer at many institutions, ultrahypofractionation could be the next step towards reducing treatment time without compromising oncologic outcomes and toxicities. MRI-guided radiotherapy could qualify as an advantageous tool as no invasive procedures have to precede in therapeutic workflows. Furthermore, MRI guidance combined with gating and plan adaptation might be essential in order to increase treatment effectivity and reduce toxicity at the same time

Astrophysics and Technical Study of a Solar Neutrino Spacecraft

We report on our study of the design of a neutrino detector, shielding and veto array needed to operate a neutrino detector in space close to the Sun. This study also took into account the expected rates of Galactic gamma and cosmic rays in addition to the particles from the Sun.These preliminary studies show that we can devise a detector such that a small signal of neutrino interactions can be extracted from a large random number of events from the background sources using a double timing method from the conversion electron produced in the neutrino interaction and a secondary delayed signal from the nuclear excited state produced from the initial neutrino interaction; in our case the conversion of Ga 69 or 71 into Ge 69 or 71, but this method could apply to other nuclei with large neutrino cross sections such as Ir 115. Although these types of events need to be above 0.405 megaelectronvolt (MeV) neutrino energy and are only 66 percent of all conversion neutrino interactions on Gallium, this is a small price to pay for an increase of 10,000 by going close to the Sun to enhance the neutrino rate over the background combatorical fake-signal events. The conclusion of this Phase-1 study is very positive in that we can get the backgrounds less than 20 percent fake signals, and in addition to this we have devised another shielding method that makes the Galactic gamma-ray rate a hundred fold less which will make further improvements over these initial estimates. Although these studies are very encouraging it suggests that the next step is a NIAC Phase-II to actually build a test device,measuring basic principles such as light attention within the scintillator with high dopants and to take data in the lab with a cosmic-ray test stand and triggered X-ray source for comparison with simulated expected performance of the detector. This would be the perfect lead into a future proposal beyond a NIAC (NASA Innovative Advanced Concepts) Phase-II for a test flight of a small one-pint detector in orbit of the detector concept beyond Earth outside of the radiation belts

Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Tumors: Initial Clinical Experience and Patient-Reported Outcomes

Purpose/ObjectiveStereotactic body radiation therapy (SBRT) has emerged as a valid treatment alternative for non-resectable liver metastases or hepatocellular carcinomas (HCC). Magnetic resonance (MR) guided SBRT has a high potential of further improving treatment quality, allowing for higher, tumoricidal irradiation doses whilst simultaneously sparing organs at risk. However, data on treatment outcome and patient acceptance is still limited.Material/MethodsWe performed a subgroup analysis of an ongoing prospective observational study comprising patients with liver metastases or HCC. Patients were treated with ablative MR-guided SBRT at the MRIdian Linac in the Department of Radiation Oncology at Heidelberg University Hospital between January 2019 and February 2020. Local control (LC) and overall survival (OS) analysis was performed using the Kaplan–Meier method. An in-house designed patient-reported outcome questionnaire was used to measure patients’ experience with the MR-Linac treatment. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE v. 5.0).ResultsTwenty patients (with n = 18 metastases; n = 2 HCC) received MR-guided SBRT for in total 26 malignant liver lesions. Median biologically effective dose (BED at α/β = 10) was 105.0 Gy (range: 67.2–112.5 Gy) and median planning target volume was 57.20 ml (range: 17.4–445.0 ml). Median treatment time was 39.0 min (range: 26.0–67.0 min). At 1-year, LC was 88.1% and OS was 84.0%. Grade I° gastrointestinal toxicity °occurred in 30.0% and grade II° in 5.0% of the patients with no grade III° or higher toxicity. Overall treatment experience was rated positively, with items scoring MR-Linac staff’s performance and items concerning the breath hold process being among the top positively rated elements. Worst scored items were treatment duration, positioning and low temperature.ConclusionMR-guided SBRT of liver tumors is a well-tolerated and well-accepted treatment modality. Initial results are promising with excellent local control and only mildest toxicity. However, prospective studies are warranted to truly assess the potential of MR-guided liver SBRT and to identify which patients profit most from this new versatile technology